DropsClinical Overview
Timolol Maleate (0.5% w/v) is a non-selective beta-1 and beta-2 adrenergic receptor antagonist on the WHO Model List of Essential Medicines. It blocks beta-adrenergic receptors on non-pigmented ciliary epithelial cells, inhibiting cyclic AMP synthesis and reducing aqueous humor secretion by 30-50% without altering pupillary size or accommodation. Indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Instill one drop into the affected eye(s) once or twice daily. Apply gentle finger pressure to the inner corner of the eye (nasolacrimal occlusion) for 2 minutes immediately after instillation to minimize systemic cardiovascular and pulmonary absorption.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Transient eye burning, stinging, dry eyes, blurred vision. Rare/Severe: Systemic beta-blocker absorption: severe bradycardia, heart block, hypotension, syncope, bronchospasm, and exacerbation of congestive heart failure.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box caution for systemic beta-blockade: Strictly contraindicated in bronchial asthma, severe COPD, sinus bradycardia, second- or third-degree AV block, and cardiogenic shock. Diabetic patients must be warned that timolol masks hypoglycemic tachycardia.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or ophthalmic treatment recommendations. Always consult a registered ophthalmologist or ENT specialist before initiating, changing, or instilling any ophthalmic or otic medication.
Timolol Maleate Eye Drops 0.5 %
Timolol Maleate (0.5% w/v) is a non-selective beta-1 and beta-2 adrenergic receptor antagonist on the WHO Model List of Essential Medicines. It blocks beta-adrenergic receptors on non-pigmented ciliary epithelial cells, inhibiting cyclic AMP synthesis and reducing aqueous humor secretion by 30-50% without altering pupillary size or accommodation. Indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.
Brimonidine Tartrate 0.2%w/v + Timolol Maleate 0.5%w/v Ophthalmic Solution
Timolol Maleate (0.5% w/v) is a non-selective beta-1 and beta-2 adrenergic receptor antagonist on the WHO Model List of Essential Medicines. It blocks beta-adrenergic receptors on non-pigmented ciliary epithelial cells, inhibiting cyclic AMP synthesis and reducing aqueous humor secretion by 30-50% without altering pupillary size or accommodation. Indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.
Dorzolamide Eye Drops 2% w/v
Topical Carbonic Anhydrase Inhibitor (Dorzolamide 2% or Brinzolamide 1% suspension, alone or with Timolol) on the WHO Model List of Essential Medicines. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes, slowing bicarbonate ion formation and reducing active sodium and fluid transport, thereby diminishing aqueous humor secretion by up to 20-30%. Indicated for intraocular pressure reduction in open-angle glaucoma and ocular hypertension.
Bimatoprost 0.03% w/v + Timolol 0.5% w/v Ophthalmic Solution
Bimatoprost (0.01%, 0.03% w/v, alone or with Timolol 0.5%) is a synthetic prostamide (cyclopentane amide) ocular hypotensive agent on the WHO Model List of Essential Medicines. It structurally mimics endogenous prostamides, binding to unique prostamide receptors to simultaneously increase both trabecular meshwork and uveoscleral aqueous humor outflow, achieving powerful intraocular pressure reduction. Indicated for the reduction of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.